Results from a First-in-Human Trial of a Novel Vascular Sealant

Background:Suture hole bleeding from synthetic grafts presents a hemostatic challenge. The designs of many vascular sealants are not optimal (non-adherence to wet surfaces, excessive swelling, inflexible). PreveLeak™ (formerly ArterX) is a polyaldehyde-bovine serum albumin-based sealant whose effica...

Full description

Bibliographic Details
Main Authors: Hans Joachim Florek, Jan eBrunkwall, Karl Heinz Orend, Ian eHandley, John P. Pribble, Ronald eDieck
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-07-01
Series:Frontiers in Surgery
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fsurg.2015.00029/full
id doaj-ef72019d06424edaa1c430d1c70a855e
record_format Article
spelling doaj-ef72019d06424edaa1c430d1c70a855e2020-11-25T00:12:07ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2015-07-01210.3389/fsurg.2015.00029150932Results from a First-in-Human Trial of a Novel Vascular SealantHans Joachim Florek0Jan eBrunkwall1Karl Heinz Orend2Ian eHandley3John P. Pribble4Ronald eDieck5Helios Kliniken FrietalUniversity Clinics, University of CologneUniversity of UlmTenaxis Medical, Inc.The Medicines CompanyTenaxis Medical, Inc.Background:Suture hole bleeding from synthetic grafts presents a hemostatic challenge. The designs of many vascular sealants are not optimal (non-adherence to wet surfaces, excessive swelling, inflexible). PreveLeak™ (formerly ArterX) is a polyaldehyde-bovine serum albumin-based sealant whose efficacy, safety, and performance were evaluated in this first-in-human study.Methods:A prospective, single-arm, multicenter study was performed in patients undergoing open vascular reconstructions with prosthetic grafts. Sealant was applied to the suture line after completion of the anastomosis. The primary endpoint was the incidence of immediate sealing (without clinically significant bleeding) upon clamp release. Secondary endpoints were time to sealing, safety, and assessment of product performance.Results:Fifty-six anastomoses were performed in 32 patients. Grafts were Dacron (66% of sites), polytetrafluoroethylene (PTFE; 32%) or both Dacron and PTFE (2%). The femoral artery was the most common site of anastomosis (41% of sites). Immediate sealing after clamp release was achieved at all anastomoses (100%); 93% had no bleeding and 7% had oozing. No rebleeding occurred during 10 minutes of observation. The 3 most common adverse events were graft or bypass occlusion (n=5 patients), infection (n=4), and seroma (n=3); none were device-related. The sealant was considered easy to apply, quickly forming a soft gel and adhering to tissue and grafts.Conclusions:PreveLeak effectively sealed anastomotic suture lines during vascular reconstruction procedures and was considered easy to use. Adverse events were consistent with those commonly observed in patients undergoing surgical procedures. These results provided the support for conducting a larger controlled clinical trial.http://journal.frontiersin.org/Journal/10.3389/fsurg.2015.00029/fullHemostasisSafetyefficacy evaluationVascular SurgeryalbuminSurgical sealant
collection DOAJ
language English
format Article
sources DOAJ
author Hans Joachim Florek
Jan eBrunkwall
Karl Heinz Orend
Ian eHandley
John P. Pribble
Ronald eDieck
spellingShingle Hans Joachim Florek
Jan eBrunkwall
Karl Heinz Orend
Ian eHandley
John P. Pribble
Ronald eDieck
Results from a First-in-Human Trial of a Novel Vascular Sealant
Frontiers in Surgery
Hemostasis
Safety
efficacy evaluation
Vascular Surgery
albumin
Surgical sealant
author_facet Hans Joachim Florek
Jan eBrunkwall
Karl Heinz Orend
Ian eHandley
John P. Pribble
Ronald eDieck
author_sort Hans Joachim Florek
title Results from a First-in-Human Trial of a Novel Vascular Sealant
title_short Results from a First-in-Human Trial of a Novel Vascular Sealant
title_full Results from a First-in-Human Trial of a Novel Vascular Sealant
title_fullStr Results from a First-in-Human Trial of a Novel Vascular Sealant
title_full_unstemmed Results from a First-in-Human Trial of a Novel Vascular Sealant
title_sort results from a first-in-human trial of a novel vascular sealant
publisher Frontiers Media S.A.
series Frontiers in Surgery
issn 2296-875X
publishDate 2015-07-01
description Background:Suture hole bleeding from synthetic grafts presents a hemostatic challenge. The designs of many vascular sealants are not optimal (non-adherence to wet surfaces, excessive swelling, inflexible). PreveLeak™ (formerly ArterX) is a polyaldehyde-bovine serum albumin-based sealant whose efficacy, safety, and performance were evaluated in this first-in-human study.Methods:A prospective, single-arm, multicenter study was performed in patients undergoing open vascular reconstructions with prosthetic grafts. Sealant was applied to the suture line after completion of the anastomosis. The primary endpoint was the incidence of immediate sealing (without clinically significant bleeding) upon clamp release. Secondary endpoints were time to sealing, safety, and assessment of product performance.Results:Fifty-six anastomoses were performed in 32 patients. Grafts were Dacron (66% of sites), polytetrafluoroethylene (PTFE; 32%) or both Dacron and PTFE (2%). The femoral artery was the most common site of anastomosis (41% of sites). Immediate sealing after clamp release was achieved at all anastomoses (100%); 93% had no bleeding and 7% had oozing. No rebleeding occurred during 10 minutes of observation. The 3 most common adverse events were graft or bypass occlusion (n=5 patients), infection (n=4), and seroma (n=3); none were device-related. The sealant was considered easy to apply, quickly forming a soft gel and adhering to tissue and grafts.Conclusions:PreveLeak effectively sealed anastomotic suture lines during vascular reconstruction procedures and was considered easy to use. Adverse events were consistent with those commonly observed in patients undergoing surgical procedures. These results provided the support for conducting a larger controlled clinical trial.
topic Hemostasis
Safety
efficacy evaluation
Vascular Surgery
albumin
Surgical sealant
url http://journal.frontiersin.org/Journal/10.3389/fsurg.2015.00029/full
work_keys_str_mv AT hansjoachimflorek resultsfromafirstinhumantrialofanovelvascularsealant
AT janebrunkwall resultsfromafirstinhumantrialofanovelvascularsealant
AT karlheinzorend resultsfromafirstinhumantrialofanovelvascularsealant
AT ianehandley resultsfromafirstinhumantrialofanovelvascularsealant
AT johnppribble resultsfromafirstinhumantrialofanovelvascularsealant
AT ronaldedieck resultsfromafirstinhumantrialofanovelvascularsealant
_version_ 1725401157138907136